INTRODUCTION
Cancer is the second leading cause of death in the US, contributing to 23.2% of all deaths (562,875 deaths) in 2007 (Xu et al., 2010) . It is estimated that 1,529,560 new cases of cancer will be diagnosed and 569,490 Americans will die of cancer in 2010 (American Cancer Society, 2010 ). An increased knowledge about the disease and its causes has resulted in identification of numerous new targets for potential anti-cancer therapies. Inhibition of poly(ADP-ribose) polymerase (PARP) has been shown to be a promising novel mechanism through targeting DNA repair. PARPs are a family of 17 enzymes that catalyze the transfer of ADP-ribose units to acceptor proteins to form ADPribose polymer, which is involved in multiple cellular processes such as replication, transcription and differentiation. PARP-1 is activated by DNA damage and is primarily responsible for initiating the repair of single-strand DNA break via a base excision repair (BER) pathway. When co-administrated with DNA-damaging chemotherapeutics, PARP inhibitors could potentiate the efficacy of these agents by preventing the repair of the damaged DNA through BER (Rouleau et al., 2010; Papeo et al., 2009 ). Thus, PARP inhibitors could be developed as chemosensitizers of DNA-damaging agents. PARP inhibitors have also demonstrated single agent effects in selected genetic backgrounds such as tumors with defects in the breast cancer associated genes (BRCA-1 and -2), the homologous recombination (HR) DNA repair regulators. PARP inhibition blocks BER pathway and results in "synthetic lethality" effects towards HR-deficient tumors (Rouleau et al., 2010; Papeo et al., 2009 ).
In addition to veliparib, several other PARP inhibitors are currently in various stages of clinical development, including iniparib, olaparib, PF-1367338, and This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on March 24, 2011 as DOI: 10.1124 at ASPET Journals on April 3, 2017 dmd.aspetjournals.org Downloaded from CEP-9722. These agents are being developed as chemopotentiators of DNA-damaging chemotherapeutics for treatment of solid tumors (e.g. melanoma and glioma), and as single agents in BRCA-deficient breast or ovarian cancers. Efficacy and safety data from Phase I and II trials demonstrated that PARP inhibitors in combination of cytotoxic agents were well tolerated and showed anti-tumor activity (Penning, 2010) .
Veliparib ((R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo [d] imidazole-4-carboxamide, Figure 1 ) is a novel and potent inhibitor of PARP-1 and PARP-2 enzymes (Ki's of 5 and 2 nM, respectively) and has demonstrated excellent in vivo efficacy in a broad spectrum of preclinical tumor models in combination with a variety of cytotoxic agents such as temozolomide (TMZ), cisplatin, cyclophosphamide and radiation (Donawho et al., 2007; Palma et al., 2009; Penning et al., 2009) . Preclinical pharmacokinetic profiles of veliparib were characterized by high plasma clearance, high volumes of distribution, and high oral bioavailability across species (Donawho et al., 2007) . A Phase 0 clinical study of veliparib showed the statistically significant inhibition of PARP activity in tumor biopsies and peripheral blood mononuclear cells at a single oral dose of 25 or 50 mg (Kummar et al., 2009) . The preliminary human pharmacokinetic profile was characterized by rapid absorption (T max : 0.5-1.5 h postdose) and primary urinary excretion (on average, 70% of dose in urine as unchanged parent drug at the 50-mg dose) (Kummar et al., 2009) . In patients receiving veliparib, the lactam metabolite M8 was shown to be a major human plasma metabolite (Wiegand et al., 2010) . Preliminary Phase I study results for veliparib in combination of TMZ in patients with solid tumors indicated that the treatment was well tolerated and demonstrated anti-tumor activity (Molina et al., 2009) . Currently, veliparib is being investigated in multiple clinical trials This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on March 24, 2011 as DOI: 10.1124 at ASPET Journals on April 3, 2017 dmd.aspetjournals.org Downloaded from for human cancers either in combination with cytotoxic agents or as a monotherapy (clinicaltrials.gov).
The objectives of the current study were as follows: 1) to characterize disposition of veliparib in rats and dogs, two animal species used for safety assessment; 2) to elucidate the structures of veliparib metabolites; 3) to characterize the interactions of veliparib with human P-glycoprotein (P-gp) and assess P-gp-mediated drug-drug interactions (DDIs); 4) to conduct in vitro assessment of DDIs mediated by cytochrome P450 enzymes (CYPs).
This article has not been copyedited and formatted. The final version may differ from this version. 
MATERIALS AND METHODS

Materials
Veliparib and its lactam metabolite (M8) were synthesized, as described previously Chromatography-grade solvents were supplied by EMD (Gibbstown, NJ) or SigmaAldrich. Supersomes were purchased from BD Gentest (Woburn, MA).
Animal Studies
Animal studies were conducted in accordance with the guidance established by the Abbott Institutional Animal Care and Use Committees. [ 3 H]Veliparib and nonradiolabeled veliparib were dissolved in a mixture of ethanol and 5 % dextrose in water (10/90, v/v) to make a dosing solution at a final concentration of 5 mg/ml . The dose volume was 1.0 ml/kg for rats and 0.5 ml/kg for dogs for both intraveneous and oral dosing. The dosed radioactivity was approximately 160 μCi/rat and 340 μCi/dog. Preand post-dosing radioactivity purities of the dose solutions were greater than 99 %.
Dosing of [ 3 H]Veliparib to Rats
Male Sprague-Dawley rats (220-300 g), age 8-12 weeks, were used in the studies.
For bile collection, six surgically-modified animals with cannulas inserted into both bile duct and duodenum (Hilltop Lab Animals, Inc, Scottsdale, PA) were acclimated for Blood samples were centrifuged to separate plasma which were then stored at -20ºC until analysis.
In Vitro Incubations with Recombinant Human CYPs (Supersomes)
The (100 pmol/ml) at 37°C for 60 min. The processed samples were analyzed by HPLC-MS/MS with radioactivity detection, as described below.
Analytical Methods
Determination of Total Radioactivity
Total radioactivity in plasma, bile, urine and cage wash was determined in Following digestion, 10 ml of Insta-Gel ® Plus scintillation cocktail was added and total radioactivity was determined by LSC.
Final radioactivity concentrations were determined from the specific activity of the dose solution using DEBRA data management software (Version 5.7.6.100, LabLogic Systems Ltd. Sheffield, UK).
Processing of Animal Samples for Metabolite Identification and Profiling
Rat plasma (90 μl) was pooled from three rats at each time point. Pooled samples were extracted with four volumes of acetonitrile/methanol (50/50, v/v), followed by vortexing and centrifugation at 3000 rpm at 4°C for 30 min using a Eppendorf 5810R Rat urine or bile samples were pooled at equal percent weight from each animal, followed by centrifugation. Supernatants were transferred to vials with inserts for HPLC-MS/MS analysis. Aliquots of individual dog urine and bile samples were filtered prior to HPLC-MS/MS analysis.
HPLC-MS/MS Analysis with Radioactivity Detection
This article has not been copyedited and formatted. The final version may differ from this version. HPLC effluent was split with a ratio of 2:8 between the mass spectrometer and an on-line radioactivity detector or a fraction collector for off-line radioactivity detection.
Isolation of M3 from Dog Urine for NMR Analysis
From the 0 to 24 h urine collected from one dog, M3 was isolated using aforementioned HPLC system. The purified M3 was desalted on an Oasis HLB solid phase extraction cartridge (Waters, Milford, MA) and then dissolved in D 2 O for NMR analysis. 1 D-and 2D-NMR experiments were conducted on a Varian Inova 500 MHz NMR spectrometer (Agilient Technologies) equipped with a SMIDG500 1.7 mm indirect detection gradient probe at Abbott Structure Chemistry Group (Abbott Park, IL).
Interactions of Veliparib with Human P-gp
Transport of Veliparib in MDR1-MDCKCells
This article has not been copyedited and formatted. The final version may differ from this version. Permeability coefficients were calculated for each sampling interval using the following equation: = mass in the receiver at time t, and ∆ t is the experimental interval. The apparent permeability, P app , is then calculated as the average: P app = (P app,1 + P app,2 + …P app, n ) /n Efflux ratio (ER) is defined as the ratio of apparent permeability between basolateral-toapical and apical-to-basolateral directions. The net flux ratio is calculated as ratio of cell monolayer was evaluated by measuring the amount of Lucifer Yellow in the receiver chambers at the end of the whole incubation period.
Inhibition of P-gp by Veliparib
The inhibition potential of veliparib (0-1000 μM) on the activity of human P-gp was evaluated in duplicate in the monolayer of Caco-2 cells (DKFZ, Heidelberg, Germany) using digoxin as the probe substrate. Caco-2 cells were grown on Transwell The Ap-to-Bl and Bl-to-Ap permeability (P app ) of digoxin and efflux ratios were calculated using the aforementioned methods.
This article has not been copyedited and formatted. The final version may differ from this version. Mass spectrometric characterization of veliparib and its metabolites are shown in Table 1 .
The proposed biotransformation pathway of veliparib in rats and dogs is shown in Figure 2 .
Absorption and Excretion of [ 3 H]Veliparib in Rats and Dogs
Mean total recovery of radioactivity after 72 h was 95.7 % in rats and 91.3 % in dog for intravenous administration, and 97.6 % in rats and 84.3 % in dog for oral administration (Table 2) . In both species, the dosed radioactivity was well absorbed and rapidly excreted in urine, with minimal radioactivity excreted in bile and feces. In rats given a 5 mg/kg intravenous This article has not been copyedited and formatted. The final version may differ from this version. (Table 2) . For oral administration, total dose recovery in 72 h was 82.7 % in urine, with 5.1 % of the dose recovered in bile, and 4.1 % in feces (Table 2) . A nearly identical excretion profile was also observed in dogs following an intravenous or oral dose of 2.5 mg/kg (Table 2 ). Urinary elimination of radioactivity was rapid with greater than 70 % of the dose excreted within 24 h in both rats and dogs. Sum of radioactivity doses recovered in urine and bile from orally treated animals indicates that at least 87.8 % of dose was absorbed in rats and 75.9 % of the dose was absorbed in dog.
Metabolism of [ 3 H]Veliparib in Rats
Veliparib was primarily excreted in rat urine as parent drug. Radioactivity profiles in the 0-24 h urine collected from intravenously dosed group showed that about 53.3 % of the dose was recovered as parent drug. In the 0-6 h bile, total radioactivity recovery was only 4.1 % of the dose, among which parent drug accounted for 0.6 % (Table 3) . A total of ten metabolites (M1-M5, and M7-M11) were characterized in rat urine and bile. The most significant metabolite was the lactam M8, representing about 21.5 % of the dose (19.6 % in urine and 1.9 % in bile). Other metabolites were minor, each representing < 3 % of the dose (Table 3) lungs (2.9), spleen (3.1), thymus (2.7), muscle (2.2), bone (1.6), skin (1.6), and heart (1.5), while lower T:P ratios were observed in testes (0.6), brain (0.3), while fat (0.3), and spinal cord (0.2) (supplemental Table 1 The inhibition potential of veliparib on the human P-gp activity was evaluated in Caco-2 monolayer using digoxin as the probe P-gp substrate at the veliparib concentrations of 0-100 μM in the first study and at 1000 μM in a second study. The efflux ratio of 9.2 for digoxin transport in Caco-2 cells was observed in the first study, and this efflux in digoxin transport was completely inhibited in the presence of the P-gp inhibitor verapmil at 30 μM (digoxin efflux ratio: 1.6). In contrast, veliparib did not demonstrate significant inhibition of the Pgp-dependent efflux of digoxin up to the highest tested concentration of 100 μM (digoxin efflux ratios: 7.5-14.7). In a second study, P-gp inhibition by veliparib was investigated in Caco-2 cells at the veliparib concentration of 1000 μM. An efflux ratio of 4.2 was observed for digoxin transport, which was inhibited by 30 μM of verapmil (digoxin efflux ratio: 1.4), but not affected by 1000 μM of veliparib (digoxin efflux ratio: 4.9).
DISCUSSION
Veliparib, a novel PARP inhibitor being developed for treatment of cancers, demonstrated high and rapid absorption. In bile duct-cannulated rats and dogs, at least 87.8 % and 75.9 % of dosed radioactivity were absorbed, respectively, consistent with high oral bioavailability (> 60 %) (Donawho et al., 2007) . Similarly in human, high absorption of veliparib was indicated by, on average, 70 % of dose being recovered as parent drug in urine (Kummar et al., 2009) . Veliparib absorption was also rapid with T max ranging from 0.5 to 2.3 h in animals and 0.5-1.5 h in humans after oral administration (Donawho et al., 2007; Kummar et al., 2009 ).
Renal secretion is the primary route of veliparib clearance. In bile duct-cannulated rats and dogs, drug-related materials were primarily eliminated in urine, with a significant portion as parent drug (> 40 % of dose). Consistently in human, about 70 % of dose was excreted in urine as parent drug. An in vitro study demonstrated that veliparib is a substrate for human organic cation transporter 2 (OCT2), a renal transporter involved in active secretion of cationic drugs (manuscript in preparation). Both in vivo excretion profiles and in vitro transporter data suggest the involvement of active renal secretion and support the conclusion that renal clearance is the primary mechanism of veliparib clearance. The excretion profile of veliparib is similar to that of varenicline, which is also primarily excreted as parent drug in urine of animals and humans, and is an OCT2 substrate (Obach et al., 2006; Feng et al., 2008) . In a clinical DDI study with cimetidine, an OCT2 inhibitor, a small increase in varenicline exposure was observed (Feng et al., 2008) . It was also indicated that moderate increase of varenicline exposure was observed in patients with renal impairment (Obach et al., 2006) . Given the similarity of clearance Metabolism plays a secondary role in veliparib clearance. In excreta of animals, metabolites contributed up to 33 % the dose. A total of 11 metabolites were characterized. The lactam M8 was the most significant metabolite in both species, accounting for 15-24 % the dose. The amino acid metabolite M3 represented approximately additional 11 % of the dose in dogs. In circulation, M8 and monooxygenated metabolite M2 were two major metabolites in rats and dogs. M3 was another major circulatory metabolite in dogs. Consistent with animal plasma profiles, M8 was a major plasma metabolite in patients receiving veliparib (Wiegand et al., 2010) . M8 was about 5 fold less potent than veliparib for in vitro PARP inhibition (K i : 23 nM) . A radiolabeled mass balance study has not been conducted in humans and radioactivity profiles of human plasma and urine are unknown. Metabolite profiling studies with non-radiolabeled human plasma samples suggested that the preliminary metabolite profile was similar to those in rats and dogs. Parent drug was the major component and three metabolites were characterized including M8 as a major metabolite, and two minor metabolites: M2 and M9 (N-carbamoyl glucuronide) (unpublished data).
Veliparib metabolism mainly occurred on the pyrrolidine to generate lactam, amino acid, N-carbamoyl glucuronide, as well as products of mono-oxygenation, and oxidation followed by dehydrogenation. Additional mono-oxygenation occurred on the benzoimidazole carboxamide. Other secondary glucuronide metabolites were formed from above primary metabolites. Pyrrolidine is well known to be metabolized to form lactam via either iminium ions or carbinolamines (Vickers and Polsky, 2000) . The amino acid metabolite is not believed to be formed from lactam hydrolysis; rather it is proposed to arise from the amino aldehydes that may be produced from ring opening of unstable carbinolamine intermediates (Vickers and Polsky, 2000) . penetration of about 57% in monkey (Donawho et al., 2007; Penning et al., 2009; Muscal et al., 2010) . Since human P-gp in BBB is primarily responsibly for limiting the entry of drugs into brain, it is important to characterize whether veliparib is a substrate for human P-gp. A previous study reported a good B:P of 0.98 in wildtype mice treated with a single intravenous dose of 10 mg/kg of veliparib. B:P increased in mdr1a/1b double knockout (KO) (4.5), bcrp KO (1.5) or triple KO mice (7.5), indicating that brain penetration of veliparib was affected by P-gp and BCRP (Fan et al., 2010) . Consistently in our study, veliparib was shown to be a weak substrate for P-gp with a low net flux ratio of 1.8 in MDR1-MDCK cells. A net flux ratio over 2 is considered a positive result for P-gp substrate (FDA, 2006) . Although veliparib is a weak substrate for P-gp and its brain penetration was affected by P-gp, due to its high permeability, veliparib could still penetrate through the BBB via passive diffusion to achieve sufficient exposure. This result would be consistent with the finding that veliparib in combination with TMZ demonstrated efficacy in a preclinical brain tumor model (Donawho et al., 2007) .
Veliparib is being investigated in clinical trials in patients with brain and CNS tumors (clinicaltrials.gov).
P-gp has also been reported to cause clinically significant DDIs via P-gp inhibition or induction, i.e. digoxin-verapamil and digoxin-rifampicin (Marchetti et al., 2007) . A number of anti-cancer chemotherapeutics such as paclitaxel, doxorubicin, and topotecan are known P-gp substrates, and are being co-administered with veliparib. To further characterize the potential DDIs of veliparib with these P-gp substrates, we evaluated whether veliparib inhibits P-gp activity using digoxin as a probe substrate in mediated efflux of digoxin in Caco-2 cells (Faessel et al., 2008) . Overall, veliparib would not be expected to have clinically significant P-gp-mediated DDIs.
In addition, veliparib is not likely to cause clinically significant DDIs mediated by
CYPs. Veliparib was metabolized in vitro by multiple recombinant human CYPs including CYP1A2, 2D6*1, 2C19 and 3A4. The highest turnover was observed with CYP2D6*1, consistent with a previous study, in which CYP2D6 was shown to be the predominant enzyme for veliparib metabolism (Li et al., 2009) . Rat data were presented as mean ± SD. This article has not been copyedited and formatted. The final version may differ from this version. 
